VotedBy VotedBy ⌕
Election Day · Tue, Nov 3See how your members of Congress voted →

S. 2828 · 111th Congress

Endocrine Disruption Prevention Act of 2009

Key: what the circles and colors mean

Each circle is a bill. The ring fills as it moves through Congress:

IntroducedPassed one chamberPassed both chambersBecame law (gold)Resolution agreed to (full, dark)Failed or vetoed (gray)

Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.

Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.

Never voted on. It didn't reach a floor vote before the 111th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.

JKD KerrySponsor
2 cosponsors · 2 D

0 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.

Endocrine Disruption Prevention Act of 2009 - Amends the Public Health Service Act to require the Director of the National Institute of Environmental Health Sciences to establish the Endocrine Disruption Prevention Program, under which the Director shall: (1) conduct and support multidisciplinary research to improve the understanding of endocrine…

What it does: CRS summary · Introduced in Senate · Dec 3, 2009

Endocrine Disruption Prevention Act of 2009 - Amends the Public Health Service Act to require the Director of the National Institute of Environmental Health Sciences to establish the Endocrine Disruption Prevention Program, under which the Director shall: (1) conduct and support multidisciplinary research to improve the understanding of endocrine disruption; and (2) conduct workshops and fora on health effects associated with environmental agents that may affect the endocrine system.

Requires the Director to establish an Endocrine Disruption Program Panel, which shall: (1) provide advice to the Director on the conduct and support of research; (2) evaluate existing population-level biomonitoring and biobanking surveillance and research programs and recommend changes needed to develop data on human exposures and effects to support the Program; and (3) develop a list of chemicals of concern for endocrine disruption effects and make findings with respect to such chemicals. Authorizes individuals to petition the Panel to determine whether a chemical should be listed or to revise a finding or determination based on new information.

Requires the Director, if the Panel finds that data are sufficient to determine that there is at least a minimal level of concern associated with a chemical's potential to disrupt the human endocrine system, to transmit the finding, including the routes and sources of exposure to the chemical, to each federal agency with authority to regulate the chemical. Requires each federal agency that receives such a transmission: (1) to reply to the Director describing the agency's regulatory authority, past actions in connection with the chemical, and proposed action to protect human health from the potential endocrine disruption effects of exposure to the chemical; and (2) within one year, to report on the actions taken and future actions proposed by the Agency in response to the Panel's finding.

Requires the Director to establish a program to support graduate and postdoctoral training in fields related to the prevention of endocrine disruption.

Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov

About this bill and sources

Official title: Endocrine Disruption Prevention Act of 2009

Latest action (Dec 3, 2009): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Policy area: Health · Origin: Senate · Introduced: Dec 3, 2009

Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)

No recorded floor vote found.